Heron Therapeutics, Inc.HRTXNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year net income growth rate
Latest
-634.78%
↓ 2967% below average
Average (39q)
-20.70%
Historical baseline
Range
High:175.56%
Low:-634.78%
CAGR
+7.5%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -634.78% |
| Q2 2025 | -190.36% |
| Q1 2025 | -28.06% |
| Q4 2024 | 175.56% |
| Q3 2024 | 47.50% |
| Q2 2024 | -192.25% |
| Q1 2024 | 70.53% |
| Q4 2023 | 57.12% |
| Q3 2023 | 40.54% |
| Q2 2023 | -28.35% |
| Q1 2023 | -64.92% |
| Q4 2022 | 52.59% |
| Q3 2022 | 25.64% |
| Q2 2022 | 11.78% |
| Q1 2022 | -16.91% |
| Q4 2021 | -4.27% |
| Q3 2021 | 14.11% |
| Q2 2021 | -15.97% |
| Q1 2021 | 15.52% |
| Q4 2020 | -6.96% |
| Q3 2020 | -5.50% |
| Q2 2020 | -7.00% |
| Q1 2020 | 10.95% |
| Q4 2019 | -72.41% |
| Q3 2019 | 33.11% |
| Q2 2019 | 20.30% |
| Q1 2019 | -27.15% |
| Q4 2018 | -29.24% |
| Q3 2018 | 0.84% |
| Q2 2018 | 26.01% |
| Q1 2018 | 16.36% |
| Q4 2017 | -49.26% |
| Q3 2017 | 2.18% |
| Q2 2017 | 14.96% |
| Q1 2017 | -4.93% |
| Q4 2016 | 1.13% |
| Q3 2016 | -12.22% |
| Q2 2016 | -29.25% |
| Q1 2016 | -7.05% |
| Q4 2015 | -37.80% |